TABLE 1. Summary of GRADE evidence tables, by treatment regimen and study population*.
| Regimen |
Population | No. of trials |
||
|---|---|---|---|---|
| Experimental regimen | Comparator regimen | Effectiveness | Toxicity | |
| 3 mos isoniazid plus rifapentine given once weekly |
9 mos isoniazid |
HIV-positive adults |
1 |
1 |
| 3 mos isoniazid plus rifapentine given once weekly |
9 mos isoniazid |
HIV-negative adults and children |
1 |
1 |
| 3 mos isoniazid plus rifapentine given once weekly |
9 mos isoniazid |
HIV-negative children |
1 |
1 |
| 3 mos isoniazid plus rifapentine given once weekly |
6 mos isoniazid |
HIV-positive adults |
1 |
1 |
| 3 mos isoniazid plus rifampin given daily |
9 mos isoniazid |
HIV-negative adults |
1 |
1 |
| 3 mos isoniazid plus rifampin given daily |
6 mos isoniazid |
HIV negative adults and children |
3 |
2 |
| 3 mos isoniazid plus rifampin given daily |
6 mos isoniazid |
HIV-positive adults |
4 |
4 |
| 3 mos isoniazid plus rifampin given daily |
Placebo or no treatment |
HIV-positive adults |
2 |
1 |
| 3 mos isoniazid plus rifampin given daily |
Placebo or no treatment |
HIV-negative adults and children |
2 |
0 |
| 4 mos rifampin given daily |
9 mos isoniazid |
HIV-negative adults |
1 |
2 |
| 4 mos rifampin given daily |
9 mos isoniazid |
HIV-negative children |
1 |
1 |
| 4 mos rifampin given daily |
6 mos isoniazid |
HIV-negative children |
1 |
0 |
| 6 mos isoniazid given daily |
Placebo |
HIV-negative adults and children |
4 |
2 |
| 6 mos isoniazid given daily |
Placebo or no treatment |
HIV-positive adults |
5 |
3 |
| 9 mos isoniazid given daily |
No treatment |
HIV-negative adults and children |
2 |
0 |
| 12 mos isoniazid given daily |
No treatment |
HIV-positive adults |
2 |
0 |
| 12 mos isoniazid given daily |
Placebo |
HIV-positive adults and children |
5 |
3 |
| 12 mos isoniazid given daily |
Placebo |
HIV-positive children |
3 |
1 |
| 12 mos isoniazid given daily |
Placebo or no treatment |
HIV-negative adults and children |
15 |
5 |
| 3 mos isoniazid plus rifapentine given once weekly |
Continuous isoniazid (up to 6 yrs) |
HIV-positive adults |
1 |
1 |
| 2 mos rifampin and pyrazinamide given daily or twice weekly | 6 mos isoniazid, 12 mos isoniazid | HIV-positive adults and children | 4 | 2 |
Abbreviation: GRADE = Grading of Recommendations Assessment, Development, and Evaluation.
* Study details and information on evidence quality are available (Supplementary Tables; https://stacks.cdc.gov/view/cdc/84235).